TF
Therapeutic Areas
Harrow Health Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IHEEZO (chloroprocaine HCl ophthalmic gel) 3% | Ocular surface anesthesia | Approved |
| TRIESENCE | Ophthalmic inflammatory conditions | Approved |
| VIGAMOX | Bacterial conjunctivitis | Approved |
| MAXITROL | Steroid-responsive inflammatory ocular conditions with infection | Approved |
| ILEVRO | Pain/inflammation associated with cataract surgery | Approved |
| NEVANAC | Pain/inflammation associated with cataract surgery | Approved |
| STELLARIS PC | Posterior Capsule Opacification (PCO) prevention | Phase 3 |
| HROW-117 (AR-117) | Allergic Conjunctivitis | Phase 2 |
Leadership Team at Harrow Health
ML
Mark L. Baum
Chief Executive Officer, Chairman of the Board, Co-Founder
AR
Andrew R. Boll
Chief Financial Officer
JW
Jamie Webb
Chief Operating Officer
SO
Seun O. Ogunro
Chief Medical Officer
DM
Drew M. Tyrrell
President, ImprimisRx
CL
Christine L. Baker
Chief Commercial Officer
PJ
Perry J. Sternberg
Board Director
RL
Richard L. Lindstrom, M.D.
Board Director